National Healthcare Properties, Inc. current report, 09 January 2020

Business Context and Reporting Period

Company: Healthcare Trust, Inc. (Note: Request metadata listed "National Healthcare Properties, Inc." but the filing text identifies the registrant as Healthcare Trust, Inc.)
Filing Type: Form 8-K (Current Report)
Date: January 9, 2020
Context: The Company announced the commencement of a self-tender offer for its common stock in response to an unsolicited tender offer by MacKenzie Capital Management, LP. The filing also details an amendment and temporary suspension of the Company's Share Repurchase Program (SRP).

Key Financial Metrics and Offer Terms

Estimated Per-Share NAV: $17.50 (as of December 31, 2018, approved April 1, 2019).
MacKenzie Offer Price: $7.99 per share (cash), less distributions paid after December 5, 2019.
Company Offer Price: $8.50 per share (cash), without reduction for distributions.
Offer Size: Up to 200,000 shares for both offers.
Expiration Date: February 7, 2020 (unless extended).
Distribution Rate: Approximately $0.85 per year per share ($0.07 per month).

Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company's operations.

Material Changes and Events

  • Commencement of Tender Offers: The Company initiated a self-tender offer at $8.50 per share to deter the MacKenzie offer, which the Board believes is undervalued at approximately 54.3% below the Estimated Per-Share NAV.
  • Share Repurchase Program (SRP) Amendment: The Board approved an amendment extending the repurchase date for requests made between July 1, 2019, and December 31, 2019, from January 31, 2020, to March 16, 2020.
  • SRP Suspension: The SRP is suspended during the pendency of the Company Offer and for 10 business days thereafter.
  • Valuation Discrepancy: The Board highlights that the MacKenzie offer price effectively reduces to no more than $7.85 per share after distribution deductions, significantly below the $17.50 NAV.

Guidance, Outlook, and Management Commentary

Board Recommendation: The Board of Directors recommends that stockholders DO NOT tender their shares in either the Company Offer or the MacKenzie Offer, as both prices are well below the current Estimated Per-Share NAV.

Liquidity and Future NAV:

  • The Company expects to publish a new Estimated Per-Share NAV as of December 31, 2019, on or around April 3, 2020.
  • There is no assurance whether the new NAV will be higher or lower than the current $17.50.
  • The Board makes no assurances regarding future distributions or the timing of future liquidity events.

Risks and Contingencies:

  • The MacKenzie Offer is irrevocable once tendered, whereas the Company Offer allows for withdrawal rights under certain conditions.
  • The Board reserves the right to amend, suspend, or terminate the Company Offer and the SRP.
  • Forward-looking statements regarding future events and NAV are subject to inherent uncertainties.

Investor Verification Checklist

  • Verify the current Estimated Per-Share NAV ($17.50 as of Dec 31, 2018) against the offer prices ($7.99 and $8.50).
  • Confirm the exact expiration date of the offers (February 7, 2020) and any potential extensions.
  • Review the "Letter to Stockholders" (Exhibit 99.1) for detailed terms of the tender offers.
  • Check the status of the Share Repurchase Program (currently suspended) and the new repurchase deadline (March 16, 2020) for prior requests.
  • Monitor the upcoming release of the new Estimated Per-Share NAV expected around April 3, 2020.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.